

**LARA SUBHAKANT SAHU**  
E 301 California Next  
Orchid Palace NIBM Road  
Pune  
Tel No: 919958218333  
PID: 1196622

Reference: Dr.--

SID: 121060641

121060641

Collection Date:

06-05-2021 12:59 PM

Sample Date:

06-05-2021 12:59 pm

Report Date:

06-05-2021 05:35 PM

F-----

Age:45.80 Years Sex:FEMALE

### Complete Blood Count

(EDTA Whole Blood)

**Hemoglobin (Hb), EDTA whole blood**

**13.30**

12.3 - 15.3 g/dL

Method: Photometry

**Total Leucocytes (WBC) count**

**6,900**

4000-10000/ $\mu$ L

Method : Coulter Principle / Microscopy

**Platelet count**

**183,000**

150000 - 450000 / $\mu$ L

Method : Coulter Principle / Microscopy

**Red blood cell (RBC) count**

**4.23**

4.10 - 5.10 x 10<sup>6</sup> / $\mu$ L

Method: Coulter Principle

**PCV (Packed Cell Volume)**

**39.70**

35.9 - 44.6 %

Method: Calculated

**MCV (Mean Corpuscular Volume)**

**93.90**

80.0 - 96.0 fL

Method: Derived from RBC histogram

**MCH (Mean Corpuscular Hb)**

**31.40**

27.5 - 33.2 pgms

Method: Calculated

**MCHC (Mean Corpuscular Hb Conc.)**

**33.50**

33.4 - 35.5 g/dL

Method: Calculated

**RDW (RBC distribution width)**

**14.10**

11.6 - 14.6 %

Method: Derived from RBC Histogram

### WBC Differential Count

Method: VCSn / Microscopy / Calculated

**Neutrophils**

**69**

40 - 80 %

**Absolute Neutrophils**

**4,761**

2000 - 7000 / $\mu$ L

**Eosinophils**

**1**

1 - 6 %

**Absolute Eosinophils**

**69**

20 - 500 / $\mu$ L

**Basophils**

**0**

0 - 2 %

**Absolute Basophils**

**0**

0 - 100 / $\mu$ L

**Lymphocytes**

**22**

20 - 40 %

**Absolute Lymphocytes**

**1,518**

1000 - 3000 / $\mu$ L

**Monocytes**

**8**

2 - 10 %

**Absolute Monocytes**

**552**

200 - 1000 / $\mu$ L

-

##\*-



Page 1 of 12

MC-3143

"Accreditation as per ISO 15189:2012, Cert.No. MC-3143. Refer scope@ www.nabl-india.org"

*Dr. Vinanti Golwilkar*

Dr.(Mrs.) Vinanti Golwilkar-Patankar  
MBBS,MD(Path) Regn.No:2008/03/0772  
A.G Diagnostics Pvt. Ltd.

Carrying forward  
Dr. Ajit Golwilkar's  
legacy of Over  
Four Decades

**DIAGNOSTICS**  
BE SURE  
BE WELL

ए.जी. डायग्नोस्टिक्स प्रा. लि. A.G Diagnostics Pvt. Ltd.  
a Neuberg associate

**Dr. Awanti Golwilkar**  
MBBS, MD (Pathology)

**Dr. Vinanti Golwilkar**  
MBBS, MD (Pathology)

LARA SUBHAKANT SAHU

E 301 Callifornia Next  
Orchid Palace NIBM Road  
Pune  
Tel No: 919958218333  
PID: 1196622

Reference:Dr.--

SID: 121060641

121060641

Collection Date:

06-05-2021 12:59 PM

Sample Date:

06-05-2021 12:59 pm

Report Date:

06-05-2021 05:35 PM

F-----

Age:45.80 Years Sex:FEMALE

**Complete Blood Count Findings**

R.B.C. : Normocytic, Normochromic

W.B.C. : No abnormality detected

Platelets : Adequate

Remark : --

•  
•  
•  
•



Page 2 of 12

"Accreditation as per ISO 15189:2012, Cert.No. MC-3143. Refer scope@ www.nabl-india.org"

*Golwilkar*

Dr.(Mrs.) Vinanti Golwilkar-Patankar  
MBBS,MD(Path) Regn.No:2008/03/0772  
A.G Diagnostics Pvt. Ltd.

Carrying forward  
Dr. Ajit Golwilkar's  
legacy of Over  
Four Decades

**DIAGNOSTICS**  
BE SURE  
BE WELL

ए.जी. डायग्नोस्टिक्स प्रा. लि. A.G Diagnostics Pvt. Ltd.  
a Neuberg associate

**Dr. Awanti Golwilkar**  
MBBS, MD (Pathology)

**Dr. Vinanti Golwilkar**  
MBBS, MD (Pathology)

LARA SUBHAKANT SAHU

E 301 California Next  
Orchid Palace NIBM Road  
Pune  
Tel No: 919958218333  
PID: 1196622

Reference:Dr.--

SID: 121060641

121060641

Collection Date:

06-05-2021 12:59 PM

Sample Date:

06-05-2021 12:59 pm

Report Date:

06-05-2021 05:35 PM

Age:45.80 Years Sex:FEMALE

## Test Description

## Observed Value Biological Reference Interval

### Lipid Profile Mini :

Cholesterol (Total), serum by Enzymatic method

**212**

Desirable : < 200 mg/dL  
Borderline high : 200 - 239 mg/dL  
High :  $\geq$  240 mg/dL

Triglycerides, serum by Enzymatic method

**84**

Normal : < 150 mg/dL  
Borderline high : 150-199 mg/dL  
High : 200-499 mg/dL  
Very high :  $\geq$  500 mg/dL

HDL Cholesterol, serum by Enzymatic method

**74**

Men : > 40 mg/dL  
Women : > 50 mg/dL

VLDL Cholesterol, serum by calculation

**17**

< 30 mg/dL

LDL Cholesterol, serum by calculation

**121**

Optimal : <100 mg/dL  
Near optimal/above optimal : 100-129 mg/dL  
Borderline high : 130-159 mg/dL  
High : 160-189 mg/dL  
Very high :  $\geq$  190 mg/dL

Cholesterol(Total)/HDL Cholesterol Ratio

**2.86**

Males : Acceptable ratio  $\leq$  5.00  
Females : Acceptable ratio  $\leq$  4.50

LDL Cholesterol/HDL Cholesterol Ratio

**1.64**

Males : Acceptable ratio  $\leq$  3.60  
Females : Acceptable ratio  $\leq$  3.20

### Reference : ATP III, NCEP Guidelines and National Lipid Association (NLA) 2014 Recommendations

As per most international and national guidelines including Lipid Association of India 2016 :

1. Lipoprotein and lipid levels should be considered in conjunction with other atherosclerotic cardiovascular disease (ASCVD) risk determinants to assess treatment goals and strategies.
2. Non-fasting lipid levels can be used in screening and in general risk estimation.



Page 3 of 12

MC-3143

"Accreditation as per ISO 15189:2012, Cert.No. MC-3143. Refer scope@ www.nabl-india.org"

*Dr. Vinanti Golwilkar*

Dr.(Mrs.) Vinanti Golwilkar-Patankar  
MBBS,MD(Path) Regn.No:2008/03/0772  
A.G Diagnostics Pvt. Ltd.

Carrying forward  
Dr. Ajit Golwilkar's  
legacy of Over  
Four Decades

**DIAGNOSTICS**

BE SURE  
BE WELL

ए.जी. डायग्नोस्टिक्स प्रा. लि. A.G Diagnostics Pvt. Ltd.  
a Neutberg associate

**Dr. Awanti Golwilkar**  
MBBS, MD (Pathology)

**Dr. Vinanti Golwilkar**  
MBBS, MD (Pathology)

**LARA SUBHAKANT SAHU**

E 301 California Next  
Orchid Palace NIBM Road  
Pune  
Tel No: 919958218333  
PID: 1196622

Reference:Dr.--

**SID: 121060641**

**121060641**

Collection Date:

06-05-2021 12:59 PM

Sample Date:

06-05-2021 12:59 pm

Report Date:

06-05-2021 05:35 PM

Age:45.80 Years Sex:FEMALE

**Test Description**

**Observed**

**Biological Reference Interval**

**Liver Function Test :**

Bilirubin-Total, serum by Diazo method	<b>0.70</b>	0.10 - 1.20 mg/dL Neonates : Upto 15.0 mg/dL
Bilirubin-Conjugated, serum by Diazo method	<b>0.20</b>	Upto 0.5 mg/dL
Bilirubin-Unconjugated, serum by calculation	<b>0.50</b>	0.1 to 1.0 mg/dL
SGOT (AST), serum by Enzymatic method	<b>21</b>	>or= 14 years : 8 - 43 U/Lt
SGPT (ALT), serum by Enzymatic Method	<b>18</b>	7 to 45 U/Lt
Alkaline Phosphatase,serum by pNPP-kinetic	<b>41</b>	Adult Female : (Unit : U/Lt.). 15 - < 17 years : 50 - 117 > or =17 years: 35 - 104
Protein (total), serum by Biuret method	<b>7.70</b>	6.4 to 8.2 g/dL
Albumin, serum by Bromocresol purple method	<b>4.60</b>	3.4 to 5.0 g/dL
Globulin, serum by calculation	<b>3.10</b>	2.3 - 3.5 g/dL

--XX--



*Golwilkar*

Dr.(Mrs.) Vinanti Golwilkar-Patankar  
MBBS,MD(Path) Regn.No:2008/03/0772  
A.G Diagnostics Pvt. Ltd.

LARA SUBHAKANT SAHU  
E 301 California Next  
Orchid Palace NIBM Road  
Pune  
Tel No: 919958218333  
PID: 1196622

Reference:Dr.--

SID: 121060641

121060641

Collection Date:

06-05-2021 12:59 PM

Sample Date:

06-05-2021 12:59 pm

Report Date:

06-05-2021 05:35 PM

Age:45.80 Years Sex:FEMALE

## Test Description

## Observed Value

## Biological Reference Interval

### TEST NAME

Glycated Hemoglobin (HbA1C), by HPLC

5.60

4.0 to 5.6 %

### Interpretation :

HbA1C level reflects the mean glucose concentration over previous 8-12 weeks and provides better indication of long term glycemic control.

### For diagnosis of Diabetes Mellitus ( $\geq 18$ yrs of age) :

5.7 % - 6.4 % : Increased risk for developing diabetes.

$\geq 6.5$  % : Diabetes

### Therapeutic goals for glycemic control :

Adults : < 7%

Toddlers and Preschoolers : < 8.5% (but > 7.5 %)

School age (6-12 yrs) : < 8%

Adolescents and young adults (13 - 19 yrs) : < 7.5 %

Levels of HbA1C may be low as result of shortened RBC life span in case of hemolytic anemia.

Increased HbA1C values may be found in patients with polycythemia or post splenectomy patients.

Patients with Homozygous forms of rare variant Hb(CC,SS,EE,SC) HbA1c can not be quantitated as there is no HbA. In such circumstances glycemic control can be monitored using plasma glucose levels or serum Fructosamine.

The A1c target should be individualized based on numerous factors, such as age, life expectancy, comorbid conditions, duration of diabetes, risk of hypoglycemia or adverse consequences from hypoglycemia, patient motivation and adherence.

Ref : ADA (Standards of Medical Care in Diabetes - 2017)



Page 5 of 12

"Accreditation as per ISO 15189:2012, Cert.No. MC-3143. Refer scope@ www.nabl-india.org"

*Dr. Vinanti Golwilkar*

Dr.(Mrs.) Vinanti Golwilkar-Patankar  
MBBS,MD(Path) Regn.No:2008/03/0772  
A.G Diagnostics Pvt. Ltd.

Carrying forward  
Dr. Ajit Golwilkar's  
legacy of Over  
Four Decades

**DIAGNOSTICS**

BE SURE  
BE WELL

ए.जी. डायग्नोस्टिक्स प्रा. लि. A.G Diagnostics Pvt. Ltd.  
a Neuberger associate

**Dr. Awanti Golwilkar**  
MBBS, MD (Pathology)

**Dr. Vinanti Golwilkar**  
MBBS, MD (Pathology)

LARA SUBHAKANT SAHU

E 301 California Next  
Orchid Palace NIBM Road  
Pune  
Tel No: 919958218333  
PID: 1196622

Reference:Dr.--

SID: 121060641

121060641

Collection Date:

06-05-2021 12:59 PM

Sample Date:

06-05-2021 12:59 pm

Report Date:

06-05-2021 05:35 PM

Age:45.80 Years Sex:FEMALE

F-----

### Test Description

### Observed Value

### Biological Reference Interval

#### Clinical Chemistry :

Urea, serum by GLDH-urease	33	17 to 49 mg/dL
BUN-Blood Urea Nitrogen,serum by calculation	15.42	8 to 23 mg/dL
Creatinine, serum by Jaffe w/o deproteinization	0.89	0.6 to 1.2 mg/dL
Uric Acid, serum by Uricase method	5.10	Female : 2.60 to 6.00 mg/dL

*\* Uric acid is useful for 1. Diagnosis and follow up of renal failure. 2. Monitoring patients receiving cytotoxic drugs and a variety of other disorders, including gout, leukemia, psoriasis, starvation and other wasting conditions . \* Increased uric acid is seen in following conditions :*

*1. Increased purine synthesis 2. Inherited metabolic disorders 3. Excess dietary purine intake 4. Increased nucleic acid turnover 5. Malignancy, cytotoxic drugs 6. Decreased urinary excretion (due to CRF) 7. Increased renal reabsorption .*

*\* Uric acid is decreased in : 1. Hepatocellular disease with reduced purine synthesis 2. Defective renal reabsorption 3. Overtreatment of uricemia (allopurinol or cancer therapies like 6-mercaptopurine, etc).*



Page 6 of 12

"Accreditation as per ISO 15189:2012, Cert.No. MC-3143. Refer scope@ www.nabl-india.org"

*Golwilkar*

Dr.(Mrs.) Vinanti Golwilkar-Patankar  
MBBS,MD(Path) Regn.No:2008/03/0772  
A.G Diagnostics Pvt. Ltd.

Carrying forward  
Dr. Ajit Golwilkar's  
legacy of Over  
Four Decades

**DIAGNOSTICS**  
BE SURE  
BE WELL

ए.जी. डायग्नोस्टिक्स प्रा. लि. A.G Diagnostics Pvt. Ltd.  
a Neuberg associate

**Dr. Awanti Golwilkar**  
MBBS, MD (Pathology)

**Dr. Vinanti Golwilkar**  
MBBS, MD (Pathology)

LARA SUBHAKANT SAHU

E 301 California Next  
Orchid Palace NIBM Road  
Pune  
Tel No: 919958218333  
PID: 1196622

Reference:Dr.--

SID: 121060641

121060641

Collection Date:

06-05-2021 12:59 PM

Sample Date:

06-05-2021 12:59 pm

Report Date:

06-05-2021 05:35 PM

Age:45.80 Years Sex:FEMALE

F-----

**Test Description**  
**Clinical Chemistry :**

**Observed Value**

**Biological Reference Interval**

**Hormones**

T3 (Total), serum by CMIA

**0.85**

0.64 to 1.52 ng/ml

T4 (Total), serum by CMIA

**7.17**

4.87 to 11.72 µg/dL

TSH(Ultrasensitive), serum by CMIA

**2.41**

For non pregnant female :

0.40 - 4.00 µIU/mL

For pregnant female :

1st trimester : 0.1 - 2.5 µIU/mL

2nd trimester : 0.2 - 3.0 µIU/mL

3rd trimester : 0.3 - 3.0 µIU/mL

Ref : American Thyroid Association  
guidelines 2017



*Golwilkar*

Dr.(Mrs.) Vinanti Golwilkar-Patankar  
MBBS,MD(Path) Regn.No:2008/03/0772  
A.G Diagnostics Pvt. Ltd.

LARA SUBHAKANT SAHU

E 301 California Next  
Orchid Palace NIBM Road  
Pune  
Tel No: 919958218333  
PID: 1196622

Reference:Dr.--

SID: 121060641

121060641

Collection Date:

06-05-2021 12:59 PM

Sample Date:

06-05-2021 12:59 pm

Report Date:

06-05-2021 05:35 PM

Age:45.80 Years Sex:FEMALE

## Test Description

## Observed Value

## Biological Reference Interval

### TEST NAME

Vitamin B12, serum by CMIA

377.0

187 - 883 pg/mL

### Interpretation :

1. Vitamin B12 (cobalamin) is necessary for hematopoiesis and normal neuronal function.
2. Vitamin B12 is decreased in

#### Decreased Serum B12

Pregnancy  
Contraceptive hormones  
Malabsorption  
Ethanol ingestion  
Smoking  
Strict vegan diet  
Pernicious anemia

3. Serum methylmalonic acid and homocysteine levels are also elevated in vitamin B12 deficiency states.

Active B12 ( Holotranscobalamin) is low in Vitamin B12 deficiency.

4. Please correlate in case of patients taking vitamin B12 supplementation.



*Golwilkar*

Dr.(Mrs.) Vinanti Golwilkar-Patankar  
MBBS,MD(Path) Regn.No:2008/03/0772  
A.G Diagnostics Pvt. Ltd.



LARA SUBHAKANT SAHU

E 301 California Next  
Orchid Palace NIBM Road  
Pune  
Tel No: 919958218333  
PID: 1196622

Reference: Dr.--

SID: 121060641

121060641

Collection Date:

06-05-2021 12:59 PM

Sample Date:

06-05-2021 12:59 pm

Report Date:

06-05-2021 05:35 PM

F-----

Age: 45.80 Years Sex: FEMALE

### Test Description

### Observed value

### Biological Reference Interval

### HOMA Index Insulin Resistance Test

Plasma glucose fasting, by Hexokinase method **84**

< 100 mg/dL  
100 to 125 mg/dL : Impaired fasting  
glucose tolerance / Prediabetes  
>= 126 mg/dL : Suggestive of  
diabetes mellitus  
(On more than one occasion)  
American Diabetes Association  
Guidelines 2020

Insulin Fasting, Serum by CMIA **2.90**

Fasting : 2.5 to 25 µU/mL  
Peak upto 150 µU/mL

HOMA IR Index **0.60**

> 2.5 indicates insulin resistance

### Interpretation

1. As, the direct measurement of the insulin effect on the blood sugar concentration is not possible other indices are used for determining an insulin resistance.
2. One of the most common indices is the HOMA index (Homeostasis Model Assessment), which is calculated according to the following formula:

HOMA index = fasting insulin (µU/ml) X fasting blood sugar (mg/dl) / 405

### 3. Indications :

- \* Adiposis (BMI > 28 kg/m<sup>2</sup>)
- \* Suspected insulin resistance (metabolic syndrome, diabetes mellitus type 2)
- \* Suspected polycystic ovary syndrome (PCO-S)
- \* Cycle disturbances (e. g. amenorrhea)
- \* Infertility

### 4. Reference ranges :

- > 2.0 indication for insulin resistance
- > 2.5 insulin resistance probable
- > 5.0 average value in patients with diabetes mellitus type 2

Reference : <https://www.bioscientia.de/en/files/2011/10/Marker>



*Golwilkar*

Dr.(Mrs.) Vinanti Golwilkar-Patankar  
MBBS,MD(Path) Regn.No:2008/03/0772  
A.G Diagnostics Pvt. Ltd.

LARA SUBHAKANT SAHU  
E 301 Callifornia Next  
Orchid Palace NIBM Road  
Pune  
Tel No: 919958218333  
PID: 1196622

Reference:Dr.--

SID: 121060641

121060641

Collection Date:

06-05-2021 12:59 PM

Sample Date:

06-05-2021 12:59 pm

Report Date:

06-05-2021 05:35 PM

Age:45.80 Years Sex:FEMALE

### Test Description

### Observed Value

### Biological Reference Interval

#### TEST NAME

25 - OH Vitamin D, serum by CMLA

25.40

Severe deficiency : < 10 ng/mL  
Mild to moderate deficiency : 10 to 19 ng/mL  
Optimum levels : 20 to 50 ng/mL  
Increased risk of hypercalciuria: 51 to 80 ng/mL  
Toxicity possible : > 80 ng/mL  
Ref. : Mayo Medical Laboratories  
These reference ranges represent  
clinical decision values, based on  
the 2011 Institute of Medicine report

### Interpretation :

Vitamin D is vital for strong bones. It also has important, emerging roles in immune function and cancer prevention.

Vitamin D compounds in the body are exogenously derived by dietary means; from plants as 25-hydroxyvitamin D2 (ergocalciferol or calciferol) or from animal products as 25-hydroxyvitamin D3 (cholecalciferol or calcidiol).

Vitamin D may also be endogenously derived by conversion of 7-dihydrocholesterol to 25-hydroxyvitamin D3 in the skin upon ultraviolet exposure.

The total 25-hydroxyvitamin D (25-OH-VitD) level (the sum of 25-OH-vitamin D2 and 25-OH-vitamin D3) is the appropriate indicator of vitamin D body stores.

Patients with renal failure can have very high 25-OH-VitD levels without any signs of toxicity, as renal conversion to the active hormone 1,25-OH-VitD is impaired or absent.

Kindly correlate clinically, with supplementation history & repeat with fresh sample if necessary.



Page 10 of 12

"Accreditation as per ISO 15189:2012, Cert.No. MC-3143. Refer scope@ www.nabl-india.org"

*Golwilkar*

Dr.(Mrs.) Vinanti Golwilkar-Patankar  
MBBS,MD(Path) Regn.No:2008/03/0772  
A.G Diagnostics Pvt. Ltd.

Carrying forward  
Dr. Ajit Golwilkar's  
legacy of Over  
Four Decades

**DIAGNOSTICS**

BE SURE  
BE WELL

ए.जी. डायग्नोस्टिक्स प्रा. लि. A.G Diagnostics Pvt. Ltd.  
a Neuberg associate

**Dr. Awanti Golwilkar**  
MBBS, MD (Pathology)

**Dr. Vinanti Golwilkar**  
MBBS, MD (Pathology)

**LARA SUBHAKANT SAHU**  
E 301 Callifornia Next  
Orchid Palace NIBM Road  
Pune  
Tel No: 919958218333  
PID: 1196622

Reference:Dr.--

**SID: 121060641**

**121060641**

Collection Date:

06-05-2021 12:59 PM

Sample Date:

06-05-2021 12:59 pm

Report Date:

06-05-2021 05:35 PM

Age:45.80 Years Sex:FEMALE

## **Urine Routine Examination**

(Sample : Urine, Automated / Semiautomated)

### **Physical**

#### **Quantity Examined**

**5.0**

ml

Method : Visual

#### **Appearance**

**Slightly Turbid**

-

Method : Visual / Automated

#### **Colour**

**Pale yellow**

-

Method : Visual / Automated

### **Chemical (Dipstick)**

#### **pH**

**5.5**

4.6 - 8.0

Method : Indicator Principle

#### **Protein**

**Absent**

Absent

Method : Sulphosalicylic Acid/ pH Indicator

#### **Glucose**

**Absent**

Absent

Method : GOD-POD / Benedict's

#### **Acetone**

**Absent**

Absent

Method : Sodium Nitroprusside reaction

#### **Bile Pigments**

**Absent**

Absent

Method : Diazo Reaction / Fouchet's test

#### **Urobilinogen**

**Not significant**

Not Significant

Method : Modified Ehrlich / Watson Schwartz

### **Microscopy / Flow cytometry**

#### **R.B.Cs**

**1-2**

0 - 2 per hpf

#### **Pus cells**

**1-2**

0 - 5 per hpf

#### **Epithelial cells**

**2-3**

0 - 5 per hpf

#### **Casts**

**Not Detected**

-

#### **Crystals**

**Not Detected**

-

-

<-->



Page 11 of 12

"Accreditation as per ISO 15189:2012, Cert.No. MC-3143. Refer scope@ www.nabl-india.org"

*Vinanti Golwilkar*

Dr.(Mrs.) Vinanti Golwilkar-Patankar  
MBBS,MD(Path) Regn.No:2008/03/0772  
A.G Diagnostics Pvt. Ltd.

Carrying forward  
Dr. Ajit Golwilkar's  
legacy of Over  
Four Decades

**DIAGNOSTICS**

BE SURE  
BE WELL

ए.जी. डायग्नोस्टिक्स प्रा. लि. A.G Diagnostics Pvt. Ltd.  
a Neuberg associate

**Dr. Awanti Golwilkar**  
MBBS, MD (Pathology)

**Dr. Vinanti Golwilkar**  
MBBS, MD (Pathology)

**LARA SUBHAKANT SAHU**

E 301 California Next  
Orchid Palace NIBM Road  
Pune  
Tel No: 919958218333  
PID: 1196622

Reference: Dr.--

**SID: 121060641**

**121060641**

Collection Date:

06-05-2021 12:59 PM

Sample Date:

06-05-2021 12:59 pm

Report Date:

06-05-2021 05:35 PM

Age: 45.80 Years Sex: FEMALE

**Test Description**

CRP(hs) - C- Reactive Protein high sensitivity

**Observed Value**

**1.12**

**Biological Reference Interval**

See clinical information below

Method : Nephelometry / Immunoturbidimetry

**Clinical Information :**

1. C-reactive protein (CRP) is a biomarker of inflammation. Plasma CRP concentrations increase rapidly and dramatically (100-fold or more) in response to tissue injury or inflammation.

2. High-sensitivity CRP (hs-CRP) is more precise than standard CRP when measuring baseline (i.e. normal) concentrations and enables a measure of chronic inflammation. It is recommended for cardiovascular risk assessment. Atherosclerosis is an inflammatory disease and hs-CRP has been endorsed by multiple guidelines as a biomarker of atherosclerotic cardiovascular disease risk.

Low cardiovascular risk : < 2.0 mg/L

High cardiovascular risk :  $\geq$  2.0 mg/L

Acute inflammation : > 10.0 mg/L

3. A single test for high-sensitivity CRP (hs-CRP) may not reflect an individual patient's basal hs-CRP level. Repeat measurement may be required to firmly establish an individual's basal hs-CRP concentration. The lowest of the measurements should be used as the predictive value.

Reference : Mayo Medical Laboratories

End of Report

Dr. (Mrs.) Vinanti Golwilkar-Patankar  
MBBS, MD(Path) Regn.No: 2008/03/0772  
A.G Diagnostics Pvt. Ltd.

Page 12 of 12

"Accreditation as per ISO 15189:2012, Cert.No. MC-3143. Refer scope@ www.nabl-india.org"

Carrying forward  
Dr. Ajit Golwilkar's  
legacy of Over  
Four Decades

**DIAGNOSTICS**

BE SURE  
BE WELL

ए.जी. डायग्नोस्टिक्स प्रा. लि. A.G Diagnostics Pvt. Ltd.  
a Neuberg associate

**Dr. Awanti Golwilkar**  
MBBS, MD (Pathology)

**Dr. Vinanti Golwilkar**  
MBBS, MD (Pathology)